A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma

Cancer Epidemiology

Volumn 33, Issue 1, 2009, Pages 37-40

  Macdonald, Kimberley ^a   Porter, Geoffrey A ^a   Guernsey, Duane L ^a   Zhao, Ronghua ^b   Casson, Alan G ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Esophageal adenocarcinoma; Insulin like growth factor I receptor; Obesity; Polymorphism

Indexed keywords

MESSENGER RNA; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; GENDER; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE GENE; IMMUNOGLOBULIN GENE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR GENE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR GENE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MULTIVARIATE ANALYSIS; OBESITY; POLYMORPHISM, GENETIC; RECEPTOR, IGF TYPE 1; RISK FACTORS;

EID: 67649872357     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.04.014     Document Type: Article

References (46)

1. Pera M., Manterola C., Vidal O., and Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 92 (2005) 151-159
2. Brown L.M., Devesa S.S., and Chow W.-H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage and age. J Natl Cancer Inst 100 (2008) 1184-1187
3. Lagergren J., Bergstrom B., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
4. Wong A., and Fitzgerald R.C. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 3 (2005) 1-10
5. Bird-Lieberman E.L., and Fitzgerald R.C. Barrett's esophagus. Gastroenterol Clin N Am 37 (2008) 921-942
6. Wild C.P., and Hardie L.J. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3 (2003) 676-684
7. McManus D.T., Olaru A., and Meltzer S.J. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 64 (2004) 1561-1569
8. Fitzgerald R.C. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55 (2006) 1810-1818
9. Shaheen N., and Ransohoff D.F. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA 287 (2002) 1972-1981
10. Casson A.G., Zheng Z., Chiasson D., MacDonald K., Riddell D.C., Guernsey J.R., et al. Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 27 (2003) 139-146
11. Whiteman D.C., Sadeghi S., Pandeya N., Smithers B.M., Gotley D.C., Bain C.J., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 57 (2008) 173-180
12. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
13. Veugelers P.J., Porter G.A., Guernsey D.L., and casson A.G. Obesity and lifestyle risk factors for gastroesophageal reflux disease. Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 19 (2006) 321-328
14. Chow W.H., Blot W.J., Vaughan T.L., Risch H.A., Gammon M.D., Stanford J.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90 (1998) 150-155
15. Lagergren J., Bergstrom R., and Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130 (1999) 883-890
16. Wu A.H., Wan P., and Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12 (2001) 721-732
17. Mayne S.T., and Navarro S.A. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 132 (2002) 3467-3470
18. Corley D.A., Kubo A., and Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 17 (2008) 352-358
19. Hampel H., Abraham N.S., and El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143 (2005) 199-211
20. Kubo A., and Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (2006) 872-878
21. Gupta K., Krishnaswamy G., Karnad A., and Peiris A.N. Insulin: a novel factor in carcinogenesis. Am J Med Sci 323 (2002) 140-145
22. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92 (2000) 1472-1489
23. Furstenberger G., and Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol 3 (2002) 298-302
24. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2 (2003) 630-635
25. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92 (2005) 2097-2101
26. Samani A.A., Yakar S., LeRoith D., and Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28 (2007) 20-47
27. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., and Kalra A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
28. Wolf I., Sadetzki S., Catane R., Karasik A., and Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 6 (2005) 103-111
29. El-Serag H.B., Hampel H., and Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4 (2006) 369-380
30. Rochester M.A., Patel N., Turney B.W., Davies D.R., Roberts I.S., Crew J., et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int 100 (2007) 1396-1401
31. Hudelist G., Wagner T., Rosner M., Fink-Retter A., Gschwantler-Kaulich D., Czerwenka K., et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer 14 (2007) 1053-1062
32. Weber M.M., Fottner C., Liu S.B., Jung M.C., Engelhardt D., and Baretton G.B. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95 (2002) 2086-2095
33. Barnard J.A., Beauchamp R.D., Russell W.E., Dubois R.N., and Coffey R.J. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 108 (1995) 564-580
34. Qureshi F.G., Tchorzewski M.T., Duncan M.D., and Harmon J.W. EGF and IGF-I synergistically stimulate proliferation of human esophageal epithelial cells. J Surg Res 69 (1997) 354-358
35. Bonafe M., Barbieri M., Marchegiani F., Olivieri F., Ragno E., Giampieri C., et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab 88 (2003) 3299-3304
36. Casson A.G., Zheng Z., Evans S.C., Geldenhuys L., van Zanten S.V., Veugelers P.J., et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 104 (2005) 730-739
37. Casson A.G., Zheng Z., Evans S.C., Veugelers P.J., Porter G.A., and Guernsey D.L. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis 26 (2005) 1536-1541
38. Balogh A., Derzbach L., Vannay A., and Vasarhelyi B. Lack of association between insulin-like growth factor I receptor G(+3174)A polymorphism and retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1035-1038
39. Rasmussen S.K., Lautier C., Hansen L., Echwald S.M., Hansen T., Ekstrom C.T., et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J Clin Endocrinol Metab 85 (2000) 1606-1610
40. Doecke J.D., Zhao Z.Z., Stark M.S., Green A.C., Hayward N.K., Montgomery G.W., et al. Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. Cancer Epidemiol Biomarkers Prev 17 (2008) 1007-1012
41. Gram I.T., Norat T., Rinaldi S., Dossus L., Lukanova A., Tehard B., et al. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond) 30 (2006) 1623-1631
42. Gunter M.J., Hoover D.R., Yu H., Wassertheil-Smoller S., Manson J.E., Li J., et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 17 (2008) 921-929
43. Moore T., Carbajal S., Beltran L., Perkins S.N., Yakar S., Leroith D., et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res 68 (2008) 3680-3688
44. Siahpush S.H., Vaughan T.L., Lampe J.N., Freeman R., Lewis S., Odze R.D., et al. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 (2007) 2387-2395
45. Chu L.W., Zhu Y., Yu K., Zheng T., Chokkalingam A.P., Stanczyk F.Z., et al. Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. Cancer Epidemiol Biomarkers Prev 17 (2008) 3268-3273
46. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10 (2001) 1239-1248